Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Affymetrix and BioDiscovery's Nexus for OncoScan Software

Premium

Affymetrix and BioDiscovery this week announced the availability of Nexus for OncoScan Software for the analysis of whole-genome copy number data generated from formalin-fixed, paraffin-embedded solid tumor samples using Affy's OncoScan FFPE Express 2.0 Service.

The offering is based on BioDiscovery's Nexus Copy Number software. The two companies said they intend to launch an updated version of the Nexus for OncoScan Software when Affy rolls out a kitted version of the assay later this year.

Using Affy's OncoScan service, customers can currently analyze highly degraded DNA in FFPE tumor samples. The company claimed that 30 cancer research institutes, including MD Anderson Cancer Center; the University of California, San Francisco; and the Huntsman Cancer Institute at the University of Utah, have all used the service.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more